Hermetica Superfood Encyclopedia
The Short Answer
Sida rhombifolia roots and aerial parts contain alkaloids (up to 161.42 μg/mg), tannins, saponins, flavonoids, and phenolic compounds that exert free radical scavenging activity via DPPH and ABTS inhibition and demonstrate anti-inflammatory effects in cell-based assays. Ethanolic extracts achieve 75–80% DPPH radical inhibition at 500 μg/mL and up to 85–90% superoxide scavenging at 1000 μg/mL in vitro, though no human clinical trials have confirmed these effects or established safe therapeutic doses.
CategoryHerb
GroupPacific Islands
Evidence LevelPreliminary
Primary KeywordSida rhombifolia benefits
Arrowleaf Sida — botanical close-up
Health Benefits
**Antioxidant Protection**
Ethanolic and aqueous extracts scavenge DPPH and ABTS free radicals at 75–80% inhibition at 500 μg/mL, with reducing power comparable to the synthetic antioxidant BHT at 100 μg/mL, attributed primarily to flavonoids and phenolic acids.
**Anti-inflammatory Activity**
Ethanol root extracts inhibit pro-inflammatory responses in cell line models, with alkaloids and phenolics demonstrating concentration-dependent inhibitory effects across a 10⁻¹²–10⁻³ M range, though specific cytokine targets remain uncharacterized in published literature.
**Antipyretic Traditional Use**
Roots have been used by Aboriginal Australian and Pacific Island communities specifically to reduce fever, a use consistent with the plant's documented anti-inflammatory and antioxidant phytochemical profile.
**Membrane Protection (Antihemolytic)**
Extracts protect erythrocyte membranes from oxidative hemolysis and lipid peroxidation, maintaining red blood cell structural integrity under oxidative stress conditions in preclinical assays.
**Antimicrobial Potential**
Phytochemical constituents including tannins, saponins, and alkaloids contribute to demonstrated antibacterial activity in vitro, with preclinical data also suggesting antiplasmodial activity relevant to traditional use in malaria-endemic Pacific regions.
**Cytostatic/Anticancer Preclinical Signals**
Cell viability studies show concentration-dependent cytotoxicity, with >90% cell survival at ≤120 μg/mL but declining to approximately 65% at 1000 μg/mL, suggesting a cytotoxic threshold that warrants further mechanistic investigation.
**Ayurvedic Tonic (Bala) Applications**
Classified in Ayurvedic medicine as 'Bala,' the plant is used for its reputed adaptogenic and restorative properties, with saponins and sterols hypothesized to contribute to this traditional use.
Origin & History
Natural habitat
Sida rhombifolia is a pantropical weed native to tropical and subtropical regions of Asia, Africa, Australia, and the Pacific Islands, thriving in disturbed soils, roadsides, and open grasslands at low to mid elevations. It is widely distributed across South and Southeast Asia, northern Australia, and numerous Pacific Island groups including Fiji, Samoa, and Papua New Guinea, where it grows as a perennial subshrub reaching 30–90 cm in height. The plant is not conventionally cultivated but is harvested from wild populations; Aboriginal Australians and Pacific Islander communities have long gathered its roots and aerial parts for medicinal preparations.
“Sida rhombifolia holds a documented place in Aboriginal Australian ethnobotany, where the roots were prepared as aqueous decoctions and applied to treat fevers and inflammatory conditions, representing one of the few pantropical weeds systematically incorporated into Indigenous Australian healing practices. Across Pacific Island cultures including those of Fiji, Samoa, and Papua New Guinea, the plant—often called 'paddy's lucerne' or 'jelly leaf' in vernacular—has been used for comparable antipyretic and wound-healing purposes, with leaves and roots employed in poultices and internal preparations. In the Indian subcontinent, Sida rhombifolia is classified in Ayurvedic medicine as a member of the 'Bala' group of plants, valued for their tonic, anti-inflammatory, and rejuvenating properties, and referenced in classical texts including the Charaka Samhita in the context of musculoskeletal and neurological ailments. The plant's widespread ethnomedicinal use across three major traditional medicine systems—Aboriginal Australian, Pacific Islander, and Ayurvedic—underscores its pharmacological significance despite the absence of modern clinical validation.”Traditional Medicine
Scientific Research
The evidence base for Sida rhombifolia consists entirely of in vitro phytochemical screening, cell viability assays, and acute in vivo toxicity studies in Albino Wistar rats; no randomized controlled trials or observational human studies have been published. In vitro antioxidant studies report reproducible quantitative outcomes—such as 75–80% DPPH inhibition at 500 μg/mL and absorbance ~1.0 in reducing power assays at 100 μg/mL—but these laboratory endpoints do not predict therapeutic efficacy or safe dosing in humans. Preclinical data also document antibacterial, antiplasmodial, and anticholinergic activity in isolated alkaloid and extract fractions, but sample sizes, effect sizes, and statistical rigor in these reports are inconsistently reported and have not been independently replicated in large-scale studies. The overall body of evidence is preliminary and restricted to lower-tier experimental designs, making translation to clinical recommendations premature.
Preparation & Dosage
Traditional preparation
**Traditional Decoction (Roots)**
Roots are boiled in water and the decoction consumed orally for fever in Aboriginal Australian and Pacific Island traditional medicine; no standardized volume or concentration has been formally documented.
**Aqueous Extract (Research)**
Used in laboratory studies at concentrations of 30–500 μg/mL for antioxidant assays; equivalent human oral doses are undefined.
**Ethanolic Root Extract (Research)**
Prepared by maceration in 70–95% ethanol; shows highest alkaloid (161.42 μg/mg), tannin (157.06 μg/mg), saponin (161.63 μg/mg), and flavonoid (80.26 μg/mg) concentrations; no capsule or standardized commercial form is currently established.
**Methanolic Extract (Research)**
Rich in squalene, vitamin E, and hexadecanoic acid; used in GC-MS phytochemical profiling rather than supplementation.
**Ethyl Acetate Extract (Research)**
Used for isolation of specific phenolic and alkaloid fractions in antimicrobial and anticholinergic studies.
**Ayurvedic 'Bala' Preparation**
In Ayurveda, root powder or paste is incorporated into classical formulations; preparation timing and harvesting window affect phytochemical yield, with longer harvest times reducing bioactive content.
**No Established Supplement Dose**
No human dose, standardization percentage, or clinical dosing interval has been established; any supplemental use outside traditional practice is experimental.
Nutritional Profile
Sida rhombifolia is not consumed as a dietary food source and lacks a conventional macronutrient or micronutrient profile reported in nutritional databases. Phytochemical analysis of root ethanolic extracts reveals high concentrations of alkaloids (161.42 μg/mg), saponins (161.63 μg/mg), tannins (157.06 μg/mg), and flavonoids (80.26 μg/mg) as primary bioactive classes. Methanolic aerial part extracts contain squalene as the most abundant lipid-class compound, followed by vitamin E (tocopherol homologs) and hexadecanoic acid (palmitic acid), contributing to its antioxidant lipid profile. Additional secondary metabolites include phenolic acids, coumarins, porphyrins, steroids, triterpenes, and anthraquinones; bioavailability of these compounds in humans has not been studied, and no data exist on absorption, distribution, metabolism, or excretion in vivo.
How It Works
Mechanism of Action
The antioxidant activity of Sida rhombifolia extracts is mediated through direct hydrogen atom or electron donation by phenolic hydroxyl groups from flavonoids and phenolic acids, quenching DPPH, ABTS, and superoxide radicals in a dose-dependent manner; superoxide scavenging is measured via NBT reduction assay and reaches 85–90% inhibition at 1000 μg/mL. Alkaloids and phenolics in aerial part extracts modulate biological targets in a biphasic, concentration-dependent manner across a wide range (10⁻¹²–10⁻³ M), suggesting receptor-level interactions—possibly adrenergic or cholinergic given reported anticholinergic activity—though specific receptor binding affinities and downstream signaling cascades have not been fully characterized. Anti-inflammatory effects observed in cell line models likely involve suppression of oxidative stress-induced membrane damage, as evidenced by antihemolytic and antilipoperoxidative assay results protecting red blood cell membranes from oxidative insult. Squalene (the most abundant fatty acid-class compound in methanolic extracts) and vitamin E analogs may contribute additional lipophilic antioxidant and membrane-stabilizing activity, complementing the water-soluble phenolic fraction.
Clinical Evidence
No human clinical trials investigating Sida rhombifolia for any indication have been identified in the available literature. The preclinical data that exists—acute toxicity studies in rats and cell viability experiments in cultured cell lines—establishes a basic safety threshold (>90% cell viability at ≤120 μg/mL) but does not constitute clinical evidence of efficacy. Without registered trials, defined patient populations, measured clinical endpoints, or reported effect sizes in humans, it is not possible to summarize clinical outcomes, confidence intervals, or number-needed-to-treat values. Confidence in the therapeutic utility of this ingredient for any human health condition remains very low until prospective human studies are conducted.
Safety & Interactions
Acute in vivo toxicity studies in Albino Wistar rats and cell viability assays indicate that Sida rhombifolia extracts are non-toxic at concentrations up to approximately 120 μg/mL (>90% cell viability), with cytotoxic effects emerging at ≥250 μg/mL and cell survival declining to ~65% at 1000 μg/mL in vitro. No human safety data, adverse event profiles, maximum tolerated doses, or pharmacokinetic parameters have been established, making it impossible to define a safe supplemental dose for human use. Reported anticholinergic activity in isolated alkaloid fractions raises a theoretical concern for interactions with cholinergic drugs (e.g., acetylcholinesterase inhibitors used in Alzheimer's disease, or muscarinic agents), and the high alkaloid content warrants caution in individuals with hepatic impairment. There are no published data on safety during pregnancy or lactation, and given the absence of human toxicology studies, use in pregnant women, nursing mothers, children, or immunocompromised individuals is not recommended.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Sida rhombifolia L.Arrowleaf SidaPaddy's LucerneBala (Ayurveda)Jelly LeafCuban JuteTeaweed
Frequently Asked Questions
What is Sida rhombifolia used for traditionally?
Sida rhombifolia roots have been used traditionally by Aboriginal Australians and Pacific Island communities primarily to reduce fever, prepared as aqueous decoctions from the roots. In Ayurvedic medicine it is classified as 'Bala' and used for anti-inflammatory, tonic, and musculoskeletal applications, though no modern clinical trials have confirmed efficacy for any of these indications.
What bioactive compounds are found in Sida rhombifolia?
Ethanolic root extracts of Sida rhombifolia contain exceptionally high concentrations of alkaloids (161.42 μg/mg), saponins (161.63 μg/mg), tannins (157.06 μg/mg), and flavonoids (80.26 μg/mg), alongside phenolic acids, steroids, triterpenes, and anthraquinones. Methanolic extracts are also rich in squalene, vitamin E homologs, and hexadecanoic acid, contributing to the plant's antioxidant lipid profile.
Is there clinical trial evidence for Sida rhombifolia?
No human clinical trials have been conducted on Sida rhombifolia for any health condition as of currently available data. The evidence is limited to in vitro antioxidant assays, cell viability studies, and acute toxicity experiments in Albino Wistar rats, which means no therapeutic dose, efficacy claim, or safety profile can be extrapolated to human use.
What is the safe dose of Sida rhombifolia extract?
No established human supplemental dose exists for Sida rhombifolia. Cell viability studies show >90% survival at ≤120 μg/mL in cultured cell lines, with toxicity increasing above 250 μg/mL, but these in vitro concentrations cannot be directly translated to oral doses in humans without pharmacokinetic and clinical safety data.
Does Sida rhombifolia have any drug interactions or safety concerns?
The isolated alkaloid fractions of Sida rhombifolia have demonstrated anticholinergic activity in preclinical assays, raising a theoretical risk of interaction with cholinergic medications such as acetylcholinesterase inhibitors (e.g., donepezil) or muscarinic agents. No human drug interaction studies exist, and use during pregnancy, lactation, or in individuals with liver disease is not recommended due to the complete absence of human safety data.
How does Sida rhombifolia compare to other herbal antioxidants in terms of free radical scavenging?
Sida rhombifolia demonstrates DPPH and ABTS free radical inhibition of 75–80% at 500 μg/mL, with reducing power comparable to the synthetic antioxidant BHT at much lower concentrations (100 μg/mL), making it competitive with other polyphenol-rich herbs. Its antioxidant activity is primarily driven by flavonoids and phenolic acids present in the plant. This performance is notable among traditional herbs used for oxidative stress management, though direct head-to-head studies with other common antioxidant herbs remain limited.
Which form of Sida rhombifolia extract (ethanolic vs. aqueous) is more effective for antioxidant and anti-inflammatory benefits?
Both ethanolic and aqueous extracts of Sida rhombifolia exhibit strong antioxidant capacity with 75–80% free radical inhibition, while ethanol root extracts show superior anti-inflammatory activity in cell-based models. Ethanolic extraction appears to concentrate alkaloids and phenolic compounds more effectively than aqueous methods for inflammatory response inhibition. The optimal choice depends on intended use, with ethanolic extracts favored for anti-inflammatory applications and aqueous extracts suitable for general antioxidant supplementation.
What populations would benefit most from Sida rhombifolia supplementation based on its bioactive properties?
Individuals seeking antioxidant and anti-inflammatory support, particularly those exposed to oxidative stress or with inflammatory concerns, would benefit most from Sida rhombifolia's flavonoid and phenolic acid content. The herb may be particularly relevant for those interested in traditional herbal approaches to cellular health and inflammatory management. However, those with specific health conditions or taking medications should consult healthcare providers before use, as alkaloid content warrants consideration in individual cases.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w sida-rhombifolia-arrowleaf-sida curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
